Understand the source comparison
Real Peptides VIP vs Competitors Quality — Comparison Table
Manufacturing Source U.S.-based 503B facilities under FDA oversight Non-503B overseas facilities, limited regulatory oversight Unregulated synthesis sites, no facility inspections 503B sourcing ensures traceability and sterility verification. Critical for rese
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Manufacturing Source
- U.S.-based 503B facilities under FDA oversight
- Non-503B overseas facilities, limited regulatory oversight
- Unregulated synthesis sites, no facility inspections
- 503B sourcing ensures traceability and sterility verification. Critical for research reproducibility
- Purity Verification
- Third-party HPLC + mass spectrometry on every batch
- Supplier-provided COA, no independent post-production testing
- COA only, no HPLC verification
- Independent HPLC catches synthesis errors and degradation missed by supplier-provided documentation
- Typical Purity Range
- 98.5–99.8% verified
- 95–98% claimed (actual 91–97%)
- 90–95% claimed (actual 85–93%)
- 2–7% purity gap translates to 15–30% variability in receptor binding affinity
- Amino-Acid Sequencing
- Confirmed via mass spec
- Not verified post-production
- Not performed
- Sequence errors cause complete experimental failure. Mass spec is non-negotiable for critical research
- Cold Chain Documentation
- Temperature-monitored U.S. shipping, 2–8°C maintained
- International shipping, no documented temperature control
- Room-temperature shipping standard
- Single temperature excursion above 8°C denatures peptide structure irreversibly
- Reconstitution Stability
- 28 days at 2–8°C, validated
- 14–21 days typical, not validated
- 7–14 days before degradation
- Short stability windows force frequent reconstitution, increasing contamination risk